Adalat Logo

Bayer HealthCare

     

Publications

Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk

an article by H. Haller

Management and treatment of angina pectoris: new evidence and new ideas with a focus on the results of the ACTION trial

an article by Philip A. Poole-Wilson

Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients

an article by Morris J. Brown and Corey B. Toal

Comparison of Two Marketed Nifedipine Modifiea-Release Formulations: An Exploratory Clinical Food Interaction Study

an article by Dr. Meinolf Wonnemann; Dr. Barbara Schug; Marias Anschütz; Dr. Brendel; Prof. Gilberto De Nucci and Prof. Henning Blume

Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects

an expert opinion by Kwo-Chang Ueng , Ming-Cheng Lin , Kuei-Chuan Chan & Chung-Sheng Lin

Nifedipine gastrointestinal therapeutic system (GITS) in the treatment of coronary heart disease and hypertension

an article by Kragten and Dunselman

The Unique Adalat Story – Nifedipine Gastrointestinal Therapeutic System

a report by Peter A Meredith

Chronic Treatment With Long-Acting Nifedipine Reduces Vasoconstricition to Endothelin-1 in Essential Hypertension

an article by Sudano, Virdis, Taddei, Spieker, Corti, Noll, Salvetti, Luscher

Read here

A review of stroke in patients with hypertension and coronary artey disease: focus on calcium channel blockers

an article by Messerli et al

Read here

The role of dihydropyridine calcium channel blockers in the treatment of hypertension and cardiovascular disease – an update

an article by Messerli, Noll, Lindholm, Haller, Ruilope, Volpe

Read here

Modified Release Nifedipine: A Review of the Use of Modified Release Formulations in the Treatment of Hypertension and Angina Pectoris

an article by Croom , Wellington

Read here

Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union

an article by Wonnemann et al

Read here